Candriam SCA’s Agile Therapeutics AGRX Stock Holding History

Candriam SCA’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15	Closed	-$28K	–	882
2021 Q3	$28K	Hold	15	–	–	﹤0.01%	851
2021 Q2	$39K	Buy	+15	New	+$49.5K	﹤0.01%	851

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's AGRX Position: Q4 2021 in Review

Candriam SCA sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 15 shares — an estimated $28K sold.

Candriam SCA first reported a position in AGRX in Q2 2021 and held it in 2 quarters. The position peaked at $39K in Q2 2021. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

Candriam SCA reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
Candriam SCA sold 15 Agile Therapeutics shares in Q4 2021, an estimated $28K.
Candriam SCA first reported a position in Agile Therapeutics in Q2 2021 and held it in 2 quarters.
Candriam SCA's Agile Therapeutics position peaked at $39K in Q2 2021.
45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.